1393179-72-0

Basic information

• Product Name: 2,6-difluoro-3-nitrophenol
• Synonyms: 2,6-difluoro-3-nitrophenol
• CAS NO: 1393179-72-0
• Molecular Weight: 175.092
• Mol File: 1393179-72-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2,6-difluoro-3-nitrophenol(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-difluoro-3-nitrophenol(1393179-72-0)
• EPA Substance Registry System: 2,6-difluoro-3-nitrophenol(1393179-72-0)

Safety Data

• Hazardous Substances Data: 1393179-72-0(Hazardous Substances Data)

Usage

General Description

2,6-difluoro-3-nitrophenol is a compound with the chemical formula C6H3F2NO3. It is a derivative of phenol with two fluorine atoms and a nitro group attached to the aromatic ring. 2,6-difluoro-3-nitrophenol is commonly used in the production of pharmaceuticals, agrochemicals, and dyes. It has a pale yellow color and is slightly soluble in water. 2,6-difluoro-3-nitrophenol is considered to be a hazardous substance and should be handled with caution due to its potential for causing irritation and harmful effects if ingested or inhaled. Additionally, it can release toxic fumes when exposed to heat or fire.

Upstream product

• 28177-48-2 2,6-difluorophenol 

Relevant articles and documents

POLYCYCLIC COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES

The present disclosure relates to bifunctional compounds, ULM— L—PTM, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A- RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.